A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VERA SEC filings page.
This page shows Vera Therapeutics, Inc. (VERA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Vera is a development-stage business where escalating research spending, not revenue, drives losses and cash needs.
In FY2025, the net loss was$299.6M while operating cash flow was-$241.1M , so accounting losses translated into nearly comparable cash use. Free cash flow was-$241.7M , reinforcing that capital spending did not materially change the cash requirement.
R&D reached
Liabilities were
Financial Health Signals
We do not publish a peer-relative financial health score for Vera Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Vera Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Vera Therapeutics, Inc. reported a net loss of $299.6M while operations used $241.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Vera Therapeutics, Inc. reported an operating loss of $315.5M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Vera Therapeutics, Inc. generated $10.3M in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Vera Therapeutics, Inc.'s EBITDA was -$94.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vera Therapeutics, Inc. reported a net loss of $93.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vera Therapeutics, Inc. earned -$1.30 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Vera Therapeutics, Inc. recorded an outflow of $99.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vera Therapeutics, Inc. held $55.3M in cash against $75.4M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Vera Therapeutics, Inc.'s gross margin was 67.9% in Q3 2026, indicating the percentage of revenue retained after direct costs.
Vera Therapeutics, Inc.'s quarterly ROE was -28.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 8.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Vera Therapeutics, Inc. invested $41.3M in research and development in Q3 2026. This represents a decrease of 27.0% from the same quarter a year earlier. Against the prior quarter it is down 31.3%.
Vera Therapeutics, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
VERA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3Mn/m | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Cost of Revenue | $3.3Mn/m | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Gross Profit | $7.0Mn/m | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| R&D Expenses | $41.3M-27.0% | $60.1M+3.2% | $86.0M+108.4% | $59.3M+77.9% | $56.5M+40.1% | $58.2M+98.5% | $41.3M+77.9% | $33.3M+60.4% |
| SG&A Expenses | $61.4M+123.7% | $52.4M+138.8% | $39.1M+145.8% | $34.9M+124.2% | $27.5M+189.4% | $21.9M+173.2% | $15.9M+101.2% | $15.6M+149.4% |
| Operating Income | -$95.7Mn/m | -$112.5Mn/m | -$125.1Mn/m | -$94.2Mn/m | -$83.9Mn/m | -$80.1Mn/m | -$57.2Mn/m | -$48.9Mn/m |
| EBITDA | -$94.9Mn/m | -$112.4Mn/m | -$125.0Mn/m | -$94.1Mn/m | -$83.8Mn/m | -$80.0Mn/m | -$57.1Mn/m | -$48.9Mn/m |
| Interest Expense | $1.9M-4.4% | $1.8M-1.4% | $1.8M+1.7% | $1.9M+1.8% | $2.0M+1.2% | $1.9M-2.0% | $1.8M-6.0% | $1.9M+77.4% |
| Net Income | -$93.7Mn/m | -$109.5Mn/m | -$121.0Mn/m | -$91.1Mn/m | -$80.3Mn/m | -$76.5Mn/m | -$51.7Mn/m | -$43.4Mn/m |
| EPS (Basic) | -$1.30n/m | -$1.52n/m | -$1.69n/m | -$1.39n/m | -$1.26n/m | -$1.20n/m | -$0.81n/m | -$0.72n/m |
| EPS (Diluted) | -$1.30n/m | -$1.52n/m | -$1.69n/m | -$1.39n/m | -$1.26n/m | -$1.20n/m | -$0.81n/m | -$0.72n/m |
| Diluted Shares (Avg) | 72M+13.0% | 72M+12.6% | 71M+12.3% | N/A | 64M+16.3% | 64M+16.6% | 64M+24.9% | N/A |
Not reported in any period shown, so not listed: Income Tax.
VERA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $465.8M-10.0% | $533.0M-7.9% | $621.7M+1.9% | $734.7M+12.1% | $517.5M+40.4% | $578.5M+45.6% | $610.2M+45.5% | $655.7M+273.5% |
| Current Assets | $441.3M-13.7% | $527.5M-7.7% | $615.8M+1.6% | $728.9M+11.9% | $511.3M+40.4% | $571.4M+44.7% | $606.1M+45.6% | $651.2M+278.6% |
| Cash & Equivalents | $55.3M-4.2% | $48.9M-0.5% | $114.4M+107.6% | $354.7M+282.9% | $57.8M+112.0% | $49.1M+95.8% | $55.1M-20.3% | $92.6M+102.8% |
| Short-Term Investments | $328.7M-25.2% | $450.3M-11.3% | $482.4M-9.8% | $359.9M-34.4% | $439.6M+34.8% | $507.7M+41.3% | $534.7M+59.8% | $548.2M+376.6% |
| Inventory | $7.1M | N/A | N/A | $0 | N/A | N/A | N/A | N/A |
| Accounts Receivable | $12.0M | N/A | N/A | $0 | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% |
| Total Liabilities | $132.6M+11.8% | $125.2M+13.6% | $122.0M+62.4% | $130.2M+65.8% | $118.6M+49.2% | $110.3M+58.8% | $75.2M+14.2% | $78.5M+6.3% |
| Current Liabilities | $55.8M+33.2% | $48.3M+44.0% | $45.1M+106.2% | $53.5M+110.7% | $41.9M+58.3% | $33.6M+82.2% | $21.9M+50.5% | $25.4M+13.8% |
| Non-Current Liabilities | $76.8M+0.1% | $76.9M+0.3% | $76.9M+44.3% | $76.8M+44.4% | $76.7M+44.7% | $76.7M+50.4% | $53.3M+3.9% | $53.2M+3.1% |
| Long-Term Debt | $75.4M+1.1% | $75.2M+1.0% | $75.0M+47.4% | $74.8M+47.6% | $74.6M+47.9% | $74.5M+48.1% | $50.9M+1.7% | $50.7M+1.6% |
| Total Equity | $333.2M-16.5% | $407.8M-12.9% | $499.7M-6.6% | $604.5M+4.7% | $398.9M+38.0% | $468.3M+42.8% | $535.0M+51.3% | $577.2M+467.6% |
| Retained Earnings | -$1.1Bn/m | -$991.4Mn/m | -$881.9Mn/m | -$760.9Mn/m | -$669.8Mn/m | -$589.5Mn/m | -$512.9Mn/m | -$461.3Mn/m |
Not reported in any period shown, so not listed: Goodwill.
VERA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$99.2Mn/m | -$100.3Mn/m | -$106.5Mn/m | -$70.0Mn/m | -$61.9Mn/m | -$54.8Mn/m | -$54.4Mn/m | -$39.2Mn/m |
| Depreciation & Amortization | $823K+538.0% | $132K+10.9% | $140K+64.7% | $135K+145.5% | $129K+437.5% | $119K+693.3% | $85K+672.7% | $55K+1275.0% |
| Stock-Based Compensation | $15.7M+61.4% | $15.9M+67.5% | $13.2M+70.6% | N/A | $9.7M+74.4% | $9.5M+94.4% | $7.7M+87.8% | N/A |
| Capital Expenditures | $0-100.0% | $0-100.0% | $23K-87.7% | $102K-84.2% | $133K-44.1% | $208K+133.7% | $187Kn/m | $645K+923.8% |
| Free Cash Flow | -$99.2Mn/m | -$100.3Mn/m | -$106.5Mn/m | -$70.1Mn/m | -$62.0Mn/m | -$55.0Mn/m | -$54.6Mn/m | -$39.8Mn/m |
| Investing Cash Flow | $101.9M+46.1% | $32.9M+15.1% | -$137.8M-999.8% | $80.7Mn/m | $69.8M+82.1% | $28.5Mn/m | $15.3Mn/m | -$221.4M-1293.1% |
| Financing Cash Flow | $3.7M+365.7% | $1.9M-90.5% | $3.9M+157.1% | $286.3M-12.2% | $797K+7.8% | $20.3M+489.9% | $1.5M-99.4% | $326.0M+1212.9% |
| Share Buybacks | N/A | N/A | N/A | $0n/m | N/A | N/A | N/A | $0n/m |
Not reported in any period shown, so not listed: Dividends Paid.
VERA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -931.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -911.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -28.1%-8.0pp | -26.9%-10.5pp | -24.2%-14.6pp | -15.1%-7.5pp | -20.1%-4.0pp | -16.3%-6.1pp | -9.7%-1.6pp | -7.5%+17.7pp |
| Return on Assets | -20.1%-4.6pp | -20.5%-7.3pp | -19.5%-11.0pp | -12.4%-5.8pp | -15.5%-2.9pp | -13.2%-4.8pp | -8.5%-1.7pp | -6.6%+8.0pp |
| Current Ratio | 7.91-4.3x | 10.92-6.1x | 13.64-14.0x | 13.64-12.0x | 12.21-1.6x | 17.03-4.4x | 27.68-0.9x | 25.67+18.0x |
| Debt-to-Equity | 0.230.0x | 0.180.0x | 0.15+0.1x | 0.120.0x | 0.190.0x | 0.160.0x | 0.100.0x | 0.09-0.4x |
| Liabilities-to-Equity | 0.40+0.1x | 0.31+0.1x | 0.24+0.1x | 0.22+0.1x | 0.300.0x | 0.240.0x | 0.140.0x | 0.14-0.6x |
| Asset Turnover | 0.020.0x | N/A | N/A | N/A | 0.00 | N/A | N/A | N/A |
| FCF Margin | -965.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vera Therapeutics, Inc. VERA | FY2025 | N/A | -$299.6M | N/A | $1.8B | — |
| Immunome, Inc. IMNM | FY2025 | $6.9M | -$212.4M | N/A | $1.9B | 50/100 |
| Aurinia Pharmaceuticals Inc AUPH | FY2025 | $283.1M | $287.2M | N/A | $2.0B | 67/100 |
| Biohaven Ltd. BHVN | FY2025 | N/A | -$738.8M | N/A | $1.9B | — |
| Septerna, Inc. SEPN | FY2025 | $46.0M | -$48.9M | N/A | $1.8B | 46/100 |
| Celldex Therapeutics, Inc CLDX | FY2025 | $1.5M | -$258.8M | N/A | $2.2B | 56/100 |
Where Vera Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Vera Therapeutics, Inc. (VERA) reported a net loss of $415.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $299.6M.
Vera Therapeutics, Inc. (VERA) had EBITDA of -$315.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Vera Therapeutics, Inc. (VERA) had $354.7M in cash and equivalents against $74.8M in long-term debt.
Vera Therapeutics, Inc. (VERA) has a return on equity of -49.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Vera Therapeutics, Inc. (VERA) recorded an outflow of $241.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Vera Therapeutics, Inc. (VERA) recorded an outflow of $241.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Vera Therapeutics, Inc. (VERA) had $734.7M in total assets as of fiscal year 2025, including both current and long-term assets.
Vera Therapeutics, Inc. (VERA) invested $630K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Vera Therapeutics, Inc. (VERA) invested $215.3M in research and development during fiscal year 2025.
Vera Therapeutics, Inc. (VERA) had a current ratio of 13.64 as of fiscal year 2025, which is generally considered healthy.
Vera Therapeutics, Inc. (VERA) had a debt-to-equity ratio of 0.12 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Vera Therapeutics, Inc. (VERA) had a liabilities-to-equity ratio of 0.22 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Vera Therapeutics, Inc. (VERA) had a return on assets of -40.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Vera Therapeutics, Inc. (VERA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Vera Therapeutics, Inc. (VERA) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Vera Therapeutics, Inc. (VERA) held $714.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $241.1M over that year. Dividing the one by the other, the reported balance equals about 36 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Vera Therapeutics, Inc. (VERA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Vera Therapeutics, Inc. (VERA) reported a net loss of $299.6M while operations used $241.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Vera Therapeutics, Inc. (VERA) reported an operating loss of $315.5M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.